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review and calculated placebo-adjusted risk ratios for achieving good pain relief
(GPR), any adverse event (AE) and withdrawal owing to intolerable AE. Direct med-
ical costs included drug acquisition and additional visits due to lack of efficacy
(poor pain relief) or intolerable AE. Unit costs were taken from local sources. Ad-
herence rates (based in number of daily doses needed) were used to estimate the
expected drug costs. All costs are expressed in 2010 USD (1USD:12.50MXN Pesos).
Utility values drawn from published literature were applied to health states. Pro-
portion of patients with GPR and quality-adjusted life years (QALY) were assessed.
RESULTS: Branded-GBP was dominated by all the other options. PGB was more
costly and less effective than DUL. Compared with branded-GBP and PGB, DUL led
to savings of $80,080 and $85,920 (per 1000 patients) USD. The incremental cost per
QALY gained with DUL used instead of generic-GBP was $8,194. This amount is
slightly lower than the estimated gross domestic product per capita in Mexico for
2010. During a second-order Monte Carlo simulation, DUL had the highest proba-
bility of being cost-effective (61%), followed by generic-GBP (25%) and PGB (14%).
CONCLUSIONS: This study suggests that DUL provides overall savings and better
health outcomes compared with branded-GBP and PGB. Administering DUL rather
than generic-GBP is a highly cost-effective intervention to manage PDPN in Mexico.
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ECONOMIC EVALUATION OF TERIPATIDE IN THE MANAGEMENT OF WOMEN
WITH POSTMENOPAUSAL OSTEOPOROSIS AND HIGH RISK OF FRAGILITY
FRACTURES IN MEXICO
Carlos F1, Clark P2, Jasqui-Romano S3
1R A C Salud Consultores, S.A. de C.V., México D.F., México, 2Hospital Infantil de México Federico
Gómez, Secretaría de Salud, México D.F., México, 3Eli Lilly and Company, México D.F., México
OBJECTIVES: Fragility fractures (FF) are associated with increased mortality, dete-
rioration in health-related quality of life and high costs. Teriparatide stimulates
bone remodeling. The aim of this study was to assess the cost and health effects of
teriparatide in women with postmenopausal osteoporosis (PMOP) and high risk of
FF from the perspective of public healthcare system in Mexico. METHODS: Target
population was women aged 70 years, with PMOP, T-score 4.0 and three clinical
risk factors, with a recent vertebral fracture not candidates to receive bisphospho-
nates. Competing alternatives were: (1) daily subcutaneous injection of teripa-
ratide 20mcg for 18 months and (2) no therapy. A Markov microsimulation model
was developed with a 30 years time horizon divided into 6-month cycles and is
composed by 5 health states: hip, vertebral, forearm and humerus fracture and
death. The incidence of FF was obtained from the FRAX® algorithms for Mexican
women. Efficacy data was gathered from placebo-controlled clinical trials of teripa-
ratide. We analyzed acquisition costs of teriparatide and medical care costs due to
FF. Frequency and location of fractures avoided and quality adjusted life years
(QALYs) were estimated. All costs are expressed in 2010 USD (1USD:12.50MXN
Pesos) RESULTS: Teriparatide avoided 324 FF per a thousand patients (hip: 43;
vertebral: 164; humerus: 35; forearm: 82). The number needed to treat (NNT) to
prevent one FF was 3.09. Teriparatide was slightly more expensive ($20,052 vs.
$22,209 USD) but more effective, with net gains of 87 QALYs per a thousand pa-
tients. The cost per additional QALY gained with teriparatide was $24,925 (below
the upper limit of 3 times the gross domestic product per capita in Mexico). Teripa-
ratide was found to be cost-effective therapy in 80% of the simulations performed
in the probabilistic sensitivity analysis. CONCLUSIONS: Teriparatide is a cost-ef-
fective intervention in women with PMOP and high risk of FF.
Gastrointestinal Disorders – Cost Studies
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RESOURCE UTILIZATION AND COST OF MANAGEMENT OF COMPLEX PERIANAL
FISTULA IN CROHN’S DISEASE IN SPAIN
Badia X1, Lara N1, Garcia-Losa M2, Zanotti C3, Orofino J3
1IMS Health, Barcelona, Spain, 2IMS Health, Madrid, Spain, 3Cellerix, SA, Tres Cantos, Spain
OBJECTIVES: To assess health care resources use and costs associated with man-
agement of complex perianal fistula in Crohn’s disease (CPCD) in Spain.METHODS:
Multicenter, retrospective and observational study conducted by 13 gastroenterol-
ogists from 11 hospitals in the Autonomous Community of Madrid, Spain. Direct
healthcare resources consumption (pharmacological treatments, laboratory/diag-
nostic tests, visits to specialists, emergency department visits and hospitaliza-
tions/surgical procedures) were recorded for 97 adult patients with CPCD active at
some time between January 1, 2005 and study data collection (4.21.5 years).
RESULTS: 527 treatments were recorded: 73.1% pharmacological (32.3% antibiotics,
20.5% immunomodulators, 20.3% biological therapies) and 26.9% surgical. Mean
per patient-year global cost was €7821.4. Percentage cost per treatment type and
[mean per patient-year cost] breakdown was 78.7% [€5773.5] pharmacological cost,
11.12% [€1027.4] hospitalizations/surgical procedures, 6.5% [€640] specialists visits,
3.4 [€350] laboratory/diagnostic tests, and 0.2%, [€30.4] emergency department vis-
its. Mean per patient-year cost per pharmacological treatment type was: €12.5
antibiotics, €1050.6 immunomodulators, and €4710.4 biological therapies.
CONCLUSIONS: Pharmacological treatments are the main cost driver of CPCD
management in Spain, being biological therapies the main component. Study
funded by Cellerix, S.A. (Spain).
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COST-EFFECTIVENESS ANALYSIS OF THE USE OF ADALIMUMAB FOR THE
TREATMENT OF CROHN’S DISEASE (CD) IN MEXICO
Mayen-Herrera E, Pozos JC, Yang M, Cortina D
Abbott Laboratories de México, México, D.F. México
OBJECTIVES: To estimate the cost-effectiveness of adalimumab CD treatment ver-
sus standard care and infliximab for patients with severe active CD. METHODS:
The model combines clinical, utility, and cost data. Four disease states (remission;
moderate; severe; very severe) based on the Crohn’s Disease Activity Index range
are used as measures of patient disease status. For the adalimumab arm, a cohort
for the proposed adalimumab regimen using actual observations from the EOW
arm in a randomized controlled clinical trial (CHARM) is used. For the standard care
arm, the model simulates patient disease states based on randomized controlled
trial data (CLASSIC I and CHARM) and calculates the probability of individuals
being in each disease state. The base-case model analyzes lifetime patient clinical
status. Hospitalization costs are estimated from the hospitalization unit cost and a
regression model based on CHARM trial data. Disease state specific non-hospital-
ization, non-anti TNF costs are summarized over time for each patient to include
other direct medical costs. For the adalimumab vs. infliximab model, the adali-
mumab regimen is compared to infliximab 5mg/kg maintenance therapy. The per-
centage of patients in remission over time is used as the measure of clinical effi-
cacy. Indirect costs are estimated based on hospitalization stays and post-
hospitalization recovery times. Costs are reported in Mexican Peso. RESULTS:
Compared to standard care, adalimumab is dominant for patients with severe CD
(cost difference -$16,825, gain in QALYs 0.1045). Adalimumab is dominant, with
lower costs and higher efficacy compared with infliximab when treating patients
with severe disease based on a societal perspective. Cost difference (adalimumab–
infliximab) were -$19,784, and including infliximab “overdosing”, the costs ac-
counted for -$42,356. Sensitivity analyses confirm the results obtained in the cost-
effectiveness analysis. CONCLUSIONS: Adalimumab maintenance therapy is
dominant over standard care. The adalimumab regimen is cost-saving over inflix-
imab 5mg/kg maintenance therapy.
PGI3
ADAPTACIÓN DE UN ANÁLISIS DE COSTO-EFECTIVIDAD DEL ENTECAVIR VS
INTERFERÓN PEGILADO ALFA A VENEZUELA
Orozco JJ1, Valencia JE2, Aiello E3, Baquero E4
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OBJECTIVOS: Mediante la adaptación a la realidad de Venezuela de un modelo
realizado por Spackman y Veenstra y previo análisis de transferibilidad, se realizó
un análisis de costo-efectividad del uso de 0.5 mg/día de entecavir versus inter-
ferón pegilado en la supresión de la replicación viral y la calidad de vida relacio-
nada con la salud en términos de QALYs en pacientes con Hepatitis B Crónica.
METODOLOGÍAS: Para la construcción de la cohorte hipotética, Spackman y Veen-
stra asumieron los datos de las eficacias así como las características de los pacien-
tes reportadas en estudios clínicos recientes. Para el análisis de transferibilidad se
siguieron los criterios de transferibilidad de la Task Force on Good Research Prac-
tices on Transferability of Economic Data de la ISPOR. En la adaptación del modelo
se asumieron las probabilidades de cambio entre estados reportadas en el estudio
original. Los costos médicos directos y de los medicamentos fueron tomados di-
rectamente del entorno local. Adicionalmente se tomaron las tablas de expectativa
de vida del observatorio de salud global de la Organización Mundial de la Salud para
Venezuela actualizadas al año 2008. Los resultados incluyeron los costos de cada
alternativa de tratamiento tanto con entecavir como con interferón pegilado, así
como los años de vida ajustados a calidad ganados. RESULTADOS: El entecavir 0.5
mg/día produjo 18,25 QALYs y una relación de costo efectividad media de 5.257 BsF
por QALY, en comparación con el interferón pegilado (marketshare) que produjo
18,12 QALYs y una relación de costo efectividad media de 7.055 BsF por QALY.
CONCLUSIONES: El entecavir a dosis de 0.5 mg/día mostró índices más bajos de
costo-efectividad media con respecto al interferón pegilado en la supresión viral en
pacientes con infección por el virus de la hepatitis B. En Venezuela, al igual que
muchos países latinoamericanos, no están establecidos umbrales de costo efectivi-
dad.
Gastrointestinal Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN PATIENTS WITH
ACTIVE CROHN’S DISEASE FOLLOWING TREATMENT WITH CERTOLIZUMAB
PEGOL IN THE MUSIC STUDY (NCT00297648)
Hébuterne X1, †Lémann M2, Coteur G3, Ernault E3, Colombel JF4
1Centre Hospitalier Universitaire de Nice, Nice, France, 2Hôpital Saint-Louis, Paris, France, 3UCB,
Braine l’Alleud, Belgium, 4Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
OBJECTIVES: MUSIC, an open-label, 1-year study of certolizumab pegol (CZP), eval-
uated the efficacy of CZP in improving pathological changes in the intestinal mu-
cosa of patients with active moderate-to-severe Crohn’s disease (CD). The purpose
of this posthoc study was to examine the relationship between CZP-mediated en-
doscopic improvement and changes in HRQoL in patients with CD. METHODS:
Patients with active CD (CD Activity Index score 225 to 450) were treated with
open-label CZP, 400 mg subcutaneously every 2 weeks for 3 doses (induction) then
400 mg every 4 weeks for up to 54 weeks (maintenance). Patients completed the
Inflammatory Bowel Disease Questionnaire (IBDQ) at baseline, Week 10, and Week
54 to assess HRQoL. An exploratory analysis of the correlation between IBDQ re-
mission (total score 170 points) and endoscopic remission (measured by a CD
Endoscopic Index of Severity score of 6 points) was performed. RESULTS: Of 89
patients entering the study, 78 patients at Week 10 and 50 patients at Week 54
completed the IBDQ. At baseline, mean IBDQ total score was 120.2. At Week 10,
mean change in IBDQ total score was 43.8 and the IBDQ remission rate was 43.8%.
At Week 54, mean change in IBDQ total score was 44.1 and the IBDQ remission rate
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was 29.2%. In patients with endoscopic remission at Week 10, the IBDQ remission
rate was 69.7% compared with 33.3% in patients not reaching endoscopic remis-
sion. Similar results were observed at Week 54. CONCLUSIONS: Treatment with
CZP at the recommended dose resulted in substantial improvement in HRQoL at 10
and 54 weeks of therapy, measured by the IBDQ. Higher rates of IBDQ remission
were associated with endoscopic remission compared with nonremission, war-
ranting further evaluation of CZP therapy on HRQoL in CD. †Dr Lémann died on
August 26, 2010. We mourn the loss of our esteemed colleague.
Health Care Use & Policy Studies – Consumer Role in Health Care
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KENYA’S VILLAGE AGING INSENSITIVITY TO AGING POLICIES
Nyabade G
Go Fishnet Youth Project, Kisumu, Nyanza, Kenya
OBJECTIVES: Since independence in Kenya in 1963, there has been great challenges
on policy making with regards to the village elderly and ageing. Inspite of our
current advocacies, sensitization and awareness programmes being carried out by
local non governmental humanitarian bodies and faith based entities, Kenyan el-
derly and ageing men and women lack government concern, services and new
policies on especially the ageing village vulnerable ill-health policy and services in
their life insurance The aim and purpose of my paper is to highlight worthy ap-
proaches and to identify areas of need as a priority in overcoming the impasse in
Kenyan policy on ageing and health. METHODS: We conducted a village research
on a door to door basis on policy and health development through Questionare as
part of a research project on dimensions and actions of health in old age in rural
communities in western Kenya and its policy implications. RESULTS: Five very
sensitive areas of evidence of lack of awareness and government lack of action to
the aged and ageing groups were highlighted. And required to (1) sensitize and give
strength to the case on why action on old age-related health should be pursued,
and (2) what action be taken to bring to light the uncertainties of the aged and
ageing groups in Kenyas most forgotten rural insensitive communities.
CONCLUSIONS: A continued formal research system on the five areas is essential
to promote awareness of policies on aged and ageing groups in the insensitive
villages and advocacy towards their ignorance and plight on matters related to
their life insurance, policy making and advancement towards scientific debate on
ageing and their health in the global community.
Health Care Use & Policy Studies – Disease Management
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DESCRIBING TRENDS AND DETERMINANTS OF NON-OPIOID ANALGESIC (NOA)
PRESCRIBING IN CHRONIC NON-CANCER PAIN PATIENTS IN THE UNITED
STATES OUTPATIENT SETTINGS
Rasu R1, Fikru B1, Vouthy KK1, Rianon N2, Agbor Bawa W1, Knell M1
1University of Missouri-Kansas City, Kansas City, MO, USA, 2University of Texas Health Science
Center-Houston, Houston, TX, USA
OBJECTIVES: Cost of prescriptions is a large portion of the nation’s health care
expenditure. In 2007, the Kaiser Family Foundation estimated total prescription
costs to be $202 billion, demonstrating a large burden to the US economy. This
study evaluates determinates of non-opioid analgesic (NOA) prescribing patterns
in the USA from the National Ambulatory Medical Care Survey (NAMCS) from
2002-2007. METHODS: NOA prescribing trends were determined using drug codes
from NAMCS data. The data was collected on patients greater than 18 years, with
ICD-9-CM codes for chronic-non-cancer pain as reasons for office visits. The study
used cross-sectional analysis. A logistic model reported determinants of NOA in
the study population. RESULTS: A total of 22,967 analgesic prescriptions were pre-
scribed from 2002-2007 for men (37%) and women (63%) 18 years or older. Men were
1.46 times more likely (p0.05) to receive NOA than Women. Medicare and Medic-
aid patients were 42% (p0.01) and 44% (p0.01) more likely to receive NOA than
patients with other insurance types. Patients seen by primary care physicians
(PCPs) were 56% (p0.05) more likely to receive NOA than by non-PCPs. Low back
pain (LBP) patients were 60% more likely to get NOA prescribed than patients with
non-LBP. Geographical location was a statistically insignificant factor relating to
the likelihood of a being prescribed NOAs. Socio-economic, education, lifestyle,
diet, age group, ethnicity, and mental health status were also found to be
insignificant. CONCLUSIONS: Men, patients with Medicare, Medicaid, and LBP
were more likely to receive prescriptions for NOA. Physicians managing patients at
risk of receiving NOA, reported in our results, may benefit from seeking evidence
based policy for maximizing pain control in a cost-effective way.
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A REVIEW OF BREAST CANCER (BC) CARE AND OUTCOMES IN LATIN AMERICA
& CARIBBEAN (LAC)
Justo N1, Wilking N2, Jönsson B3
1i3 Innovus, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Stockholm School of
Economics, Stockholm, Sweden
OBJECTIVES: Provide an overview of the burden of BC and of BC care and outcomes
in LAC.METHODS: Review of literature (PubMed, LILACS, SCIELO), public databases
(Globocan 2002 & 2008, CEPALSTAT, DIRAC, PAHO, WHOSYS, etc) and conference
presentations (ASCO, ISPOR). Latin-American experts and patient organizations
were surveyed. RESULTS: A total of 114,900 women present with and 37,000 die of
BC annually in LAC. BC exhibits the highest incidence and mortality of all cancers,
is steadily increasing and is expected to double by 2030. Age is the principal risk
factor. High incidence in Argentina and Uruguay (ASR 74-91/100,000) and younger
age at diagnosis and death (mean 57y) in Peru, Mexico, Colombia and Brazil trans-
late into a heavy burden. LAC’s low 5-year survival (70-75%) is partly because
30-40% patients are diagnosed in metastatic phases III and IV. However, BC mor-
tality-to-incidence ratios (MIR) improvements are noticeable when comparing
MIR2002 vs. MIR2008. Best MIRs are registered in Argentina, Uruguay and Chile.
Costa Rica shows the most progress; Brazil, Mexico and Panama have not improved
significantly. Suboptimal prevention policies; vast inequalities in access to diagno-
sis and treatment, a fragmented organisation and management of BC care, and
poor uptake of evidence-based best practices were observed. Universal healthcare
coverage is not the rule in LAC and, even in those countries where access to BC
health services is guaranteed by law; resources are insufficient. Availability of BC-
specialized surgeons, waiting times, node clearance policy and access to breast
reconstruction vary greatly across countries and between public and private set-
tings. Radiotherapy equipment is insufficient (except Uruguay, Chile, Venezuela).
All modern systemic therapies are available but some not widely diffused for cost
considerations. Palliative care is developing but, despite great efforts, many prob-
lems persist. CONCLUSIONS: Women go undiagnosed, uncared for or treated with
suboptimal therapies; which results in high morbidity and associated societal
costs.
Health Care Use & Policy Studies – Drug/Device/Diagnostic Use & Policy
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SIGNIFICANT DECREASE IN THE HUNGARIAN HEALTH INSURANCE
PHARMACEUTICAL BUDGET BETWEEN 2006-2009
Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Integra Consulting zRt., Budapest, Hungary, 3Institute of
Experimental Medicine (IEM)., Budapest, Hungary
OBJECTIVES: At the end of 2006, there was an important reform in the Hungarian
pharmaceutical market, including serious changes in the health insurance reim-
bursement of medicines. The aim of our study is to analyze the changes in the
Hungarian health insurance pharmaceutical budget between 2006-2009.
METHODS: Data were derived from the nationwide administrative dataset of the
National Health Insurance Fund Administration (OEP), the only health care financ-
ing agency in Hungary. We analyzed the changes of the pharmaceutical budget
between 2006-2009. Results are given in Hungarian Forint (HUF), US dollars (USD)
and Euro (EUR). The annual average currency exchange rates were applied accord-
ing to the data of the Central Bank of Hungary. RESULTS: In the first year, the
Hungarian pharmaceutical budget decreased from 388.7 billion HUF (2006) to 323.6
billion HUF (2007) by 65.1 billion HUF (16.7 %). This decrease was a bit moderate
both in Euro (0.18 billion EUR, 12.4 %) and in USD dollar (0.1 billion USD, 4.7 %) due
to the stronger Hungarian currency. For 2009, the pharmaceutical budget slightly
increased compared to 2007 up to 343.2 billion HUF which resulted in a decrease
from 2006 to 2009 by 45.5 billion HUF (11.7 %). The decrease between 2006-2009 was
more significant both in Euro (0.25 billion EUR, 16.8 %) and in USD dollar (0.15 billion
USD, 8.1 %) due to the weakened Hungarian currency. CONCLUSIONS: Due to the
reform of the whole Hungarian pharmaceutical market, the Hungarian health in-
surance pharmaceutical budget significantly decreased between 2006-2009. This
decrease was moderate in EUR or USD between 2006-2007, however between 2006-
2009 it became higher as the Hungarian currency weakened compared to EUR or
USD during the world economic crisis.
PHP5
MODELO TEORICO DE UN CONSUMIDOR: SELECCION ENTRE UN BIOSIMILAR Y
UN BIOTECNOLOGICO DE PATENTE BASADO EN PREFERENCIAS
Lechuga D
ITAM, México, D.F., México
OBJECTIVOS: Realizar un análisis teórico de las preferencias del paciente derivado
de la elección entre dos bienes: un medicamento biotecnológico de patente y un
medicamento biosimilar. METODOLOGÍAS: Suponemos que son bienes sustitutos
perfectos, pues el paciente no puede consumir los dos bienes al mismo tiempo,
debe elegir entre uno u otro. Definimos la función de utilidad del paciente como
U(BT,BS)aBTbBS. Donde, BT es el Biotecnológico de patente, BS Biosimilar, a es la
seguridad y eficacia del medicamento BT y b seguridad y eficacia del medicamento
BS. Entre más seguro y eficaz sea el medicamento el paciente lo prefiere más. Entre
mayor sea U su estado de salud es mejor. Suponemos que BT tiene estudios clínicos
confiables que demuestran su seguridad y eficacia y que BS no presenta estudios
clínicos y no se sabe su seguridad y eficacia real, por lo tanto BT es preferido, es
decir ab. El paciente posee una restricción presupuestal determinada por la ec-
uación yPBTBTPBSBS. Derivado de las inversiones en estudios clínicos supo-
nemos que PBTPBS. La tasa marginal de sustitución está determinada por la pen-
diente -a/b, es decir que el paciente sacrificará una unidad de BT por b/a unidades
del bien BS. Dada la restricción presupuestal, la pendiente y tasa de sustitución
objetivo es -PBT/PBS. RESULTADOS: De acuerdo a las preferencias del consumidor,
su consumo óptimo se determinan de acuerdo a lo siguiente, si PBT/PBSa/b solo
consumirá BT, si PBT/PBSa/b entonces el paciente solo consumirá BS, y si PBT/
PBSa/b el paciente está indiferente entre consumir BT o BS. CONCLUSIONES:
Podemos concluir que las preferencias del paciente son sensibles al precio y a la
seguridad y eficacia del medicamento. Entre más seguro y eficaz sea BT el paciente
lo prefiere y estará dispuesto a pagar más.
PHP6
CUADRO BÁSICO Y CATÁLOGO DE MEDICAMENTOS DEL SECTOR SALUD: ES
ACTUALMENTE UN REFERENTE PARA LAS INSTITUCIONES PÚBLICAS Y/O
CUMPLE CON LOS OBJETIVOS DE SU CREACIÓN
Rivera-Peña G1, Vargas-Palacios A2, Barraza-Llorens M3, Gutierrez-Delgado C1
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